about
Are biological drugs safe in pregnancy?OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritisMud-bath treatment in spondylitis associated with inflammatory bowel disease--a pilot randomised clinical trialDiagnosis and classification of relapsing polychondritisEULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Working the endless puzzle of hereditary autoinflammatory disorders.High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals.Biological treatments in Behçet's disease: beyond anti-TNF therapy.The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacemenIdentification of a central role for complement in osteoarthritis.Overlap connective tissue disease syndromes.Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases.Clinical significance of cytokine determination in synovial fluid.Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression.EULAR recommendations for calcium pyrophosphate deposition. Part II: management.The clinical features, diagnosis and classification of dermatomyositis.Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active diseaseEULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease.The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathwayOARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group.Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.Chronic autoimmune thyroiditis and rheumatic manifestations.Tinnitus and bilateral sensorineural hearing loss: ankylosing spondylitis or a side-effect of sulphasalazine treatment?Effect of pregnancy on serum cytokines in SLE patientsNew biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment.Biomechanical assessment of balance and posture in subjects with ankylosing spondylitis.Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis.The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersClinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review.Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issuesEULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee.Arthrocentesis and synovial fluid analysis in clinical practice: value of sonography in difficult cases.Methods used to assess remission and low disease activity in rheumatoid arthritis.Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR).International position paper on febuxostat.
P50
Q28081758-379357F1-E56C-4FBC-AF6E-59A657F68D91Q28083591-AB21CE77-1F48-43EE-95DD-D0D10BD1279CQ28217596-DF7DAEFC-AD35-48BD-B4BA-1227D5F9804AQ28306563-AF3A1A94-2C04-4CE6-B1AE-45A2615400D0Q31119321-07B54BA7-56EB-4CF0-9DB6-DCBEFA32D420Q33260652-E28B34F6-7E66-43A1-948F-A007EC285EC4Q33357128-21936DB2-D271-416B-83A2-C7E8805942D0Q33873710-CA104EF2-085E-4E70-85A0-E078F9129315Q33908217-7BA282F6-EE15-450A-A570-6BD2B0B59676Q34118968-9E0B8E1B-9E09-4FC4-9551-29CA2A34CA59Q34230334-AB738035-2174-488B-9613-AEA977C21F21Q34284779-1A1ECC1C-11F8-4409-A0E0-F30405CD8043Q34424268-138D6473-513E-40CF-A1BB-0C7962947AE7Q34559795-250DF622-ED88-4C5F-B72F-D5486FEE70C3Q34586059-29019548-ADDF-411E-A3AB-4826F32D4993Q34626526-ADE64A56-38DE-4771-A27F-52F4D295F8EEQ34659254-3688457E-0276-47D2-9C09-634F46DAC27EQ34949611-26938CCA-70F0-41F2-BF61-A0DF5D74ADA2Q35003750-1ABE0998-7459-4B96-8E07-B5768898AAE5Q35552247-63A0F7BE-31C8-4798-9E18-A2257EAADF2EQ35559391-BA81B39D-B85B-4419-BF82-1FDB3AE3E7F3Q35678507-C1D45AA3-3164-432D-8C9A-927DC9970662Q35708834-C1A36D6F-B036-46D8-88EE-886C73627FAAQ35853436-BF359025-9853-4E1C-A71F-CB2D31F18074Q36217152-C4AEFFFC-8F52-437D-9164-4C7C6EF80C00Q36245748-65B44F2D-EE18-465C-8E10-284D7AAB0F5BQ36310851-223EDCD3-6B5A-4C50-9FC7-86FE56EC5640Q36455068-2FF4ABA8-4071-43CC-A568-49FB2F0A58AEQ36940165-C21D6EB3-83A8-4191-B3CE-199F73CF96F0Q36940942-AAB47388-8C18-449C-AF3E-D7DD52FFFA30Q37077105-7A4F10AD-DDA2-410F-8FCF-47935703D05FQ37077564-4ADFEFAC-77EE-4174-AF54-A3FF4A908B7BQ37249057-993160E5-1768-412F-9BEE-830CE06B8529Q37249170-999FB177-23FE-4760-BAD7-E4CA4D47A4CCQ37299354-0401EC82-5F75-45DD-BD0A-067A46A6F431Q37369605-0A8357B7-EEA9-438A-8C15-C06757DEE331Q37403701-138673C0-16A6-4A09-A5C0-4CA670DAABFDQ37551323-A7C97E9D-78B5-422D-9677-3664D91F60FAQ37691084-A0051C93-4D39-446A-9A25-085B5B31DB85Q37733344-8C95C6E0-C71B-44D5-AB7E-270628541814
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Leonardo Punzi
@ast
Leonardo Punzi
@en
Leonardo Punzi
@es
Leonardo Punzi
@nl
type
label
Leonardo Punzi
@ast
Leonardo Punzi
@en
Leonardo Punzi
@es
Leonardo Punzi
@nl
prefLabel
Leonardo Punzi
@ast
Leonardo Punzi
@en
Leonardo Punzi
@es
Leonardo Punzi
@nl
P106
P1153
7005080858
P21
P31
P496
0000-0002-8853-516X